Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation

Mohammad Chehelgerdi, Matin Chehelgerdi, Omer Qutaiba B. Allela, Renzon Daniel Cosme Pecho, Narayanan Jayasankar, Devendra Pratap Rao, Tamilanban Thamaraikani, Manimaran Vasanthan, Patrik Viktor, Natrayan Lakshmaiya, Mohamed J. Saadh, Ayesha Amajd, Mabrouk A. Abo-Zaid, Roxana Yolanda Castillo-Acobo, Ahmed H. Ismail, Ali H. Amin, Reza Akhavan-Sigari

Research output: Contribution to journalReview articlepeer-review

Abstract

The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers for medicinal purposes have been approved for human trials, only a few have been authorized for clinical use in targeting cancer cells. In this review, we analyze some of the authorized formulations and discuss the challenges of translating findings from the lab to the clinic. This study highlights the various nanocarriers and compounds that can be used for selective tumor targeting and the inherent difficulties in cancer therapy. Nanotechnology provides a promising platform for improving cancer detection and treatment in the future, but further research is needed to overcome the current limitations in clinical translation. Graphical Abstract: [Figure not available: see fulltext.]

Original languageEnglish
Article number169
JournalMolecular Cancer
Volume22
Issue number1
DOIs
StatePublished - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023, BioMed Central Ltd., part of Springer Nature.

Keywords

  • Cancer detection
  • Cancer treatment
  • Human trials
  • Materials science
  • Medicinal purposes
  • Nanocarriers
  • Nanoscale targeting techniques
  • Nanotechnology
  • Protein engineering

Fingerprint

Dive into the research topics of 'Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation'. Together they form a unique fingerprint.

Cite this